OncoMatch/Clinical Trials/NCT06789757
The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)
Is NCT06789757 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Memantine Hydrochloride and Bevacizumab for hepatocellular carcinoma.
Treatment: Memantine Hydrochloride · Bevacizumab · Atezolizumab — The purpose of this research is to see the effect of triplet therapy with atezolizumab, bevacizumab, and memantine in treatment of your hepatocellular carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: memantine (memantine)
Patients already on memantine for any reason prior to enrollment will be excluded
Lab requirements
Blood counts
Absolute Neutrophil Count ≥ 1,500/μL; Platelets ≥ 100,000/μL; Hemoglobin ≥ 90 g/L (9g/dL)
Kidney function
Creatinine ≤ 2.0 mg/dL; eGFR (using Cockcroft Gault equation) > 40ml/min
Liver function
Childs-Pugh cirrhosis score of A5 or A6; Total Bilirubin ≤ 3 x ULN; AST(SGOT)/ALT(SGPT)/Alkaline Phosphatase ≤ 3 x ULN Or ≤5x ULN if due to liver involvement by tumor
Cardiac function
No significant cardiovascular disease (such as NYHA Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina
Patients must have bone marrow and organ function as defined below: Absolute Neutrophil Count ≥ 1,500/μL; Platelets ≥ 100,000/μL; Hemoglobin ≥ 90 g/L (9g/dL); Total Bilirubin ≤ 3 x ULN; AST(SGOT)/ALT(SGPT)/Alkaline Phosphatase ≤ 3 x ULN Or ≤5x ULN if due to liver involvement by tumor; Creatinine ≤ 2.0 mg/dL; eGFR (using Cockcroft Gault equation) > 40ml/min. Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Inova Schar Cancer Institute - Fair Oaks · Fairfax, Virginia
- Inova Health Care Service · Falls Church, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify